Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Aug 4;26(3):387-397.
doi: 10.5935/1518-0557.20210077.

Evaluation of Protocols of Controlled Ovarian Stimulation in Obtaining Mature Oocytes (MII): Retrospective Study on Assisted Reproductive Technology Procedures

Cátia Manuela Ribeiro Barbosa Martins  1 , Patrícia Cordeiro Pires de Figueiredo Gomes Crisóstomo Ruivo  1   2 , Denise Cristina Mós Vaz-Oliani  1   2   3 , Renato Alessandre Silva Martins  1   2 , Antonio Helio Oliani  1   2   3
Affiliations

Evaluation of Protocols of Controlled Ovarian Stimulation in Obtaining Mature Oocytes (MII): Retrospective Study on Assisted Reproductive Technology Procedures

Cátia Manuela Ribeiro Barbosa Martins et al. JBRA Assist Reprod. .

Abstract

Objective: To understand which of the controlled ovarian stimulation (COS) protocols used in different patients are associated with greater amounts of oocytes retrieved.

Methods: The study population was divided into three groups, considering AMH and AFC to obtain the Ovarian Response Predictor Index (ORPI); they were grouped into: G1-Low Reserve (ORPI <0.5); G2-Normal Reserve (ORPI:0.5-0.9); and G3-High Reserve (ORPI≥0.9). 246 cycles were selected in which COS was used: recombinant FSH - follitropin alfa or beta (Protocol 1) or corifollitropin alfa (Protocol 2), both associated with urinary HMG and the GnRH antagonist, with the trigger performed using recombinant hCG or GnRH agonist.

Results: The number of oocytes obtained was higher in protocol 1 in all groups, with higher counts seen in G1 than in G2 or G3. The number of days required in COS for protocol 2 was greater than for protocol 1 in all groups. The total dose of recombinant FSH alfa or beta / urinary HMG used in protocol 1 was inversely proportional to the ovarian reserve. The lower the ORPI, the greater the average number of international units administered. In protocol 2, there was a need to supplement with higher doses of urinary HMG when compared to protocol 1. The dosage of the GnRH antagonist was dependent on the number of COS days until the trigger was used. In obtaining MII oocytes, the percentages were similar regardless of the trigger used.

Conclusions: The use of follitropin leads to greater numbers of retrieved oocytes than corifollitropin alfa in all ORPIs. The dose of recombinant FSH used with urinary HMG increases inversely proportional to the ORPI value. The fixed dose of recombinant FSH deposit requires a sharp increase in the dose of urinary HMG.

Keywords: anti-Müllerian hormone; antral follicle count; assisted reproductive technology; controlled ovarian stimulation; infertility.

PubMed Disclaimer

Conflict of interest statement

CONFLICT OF INTEREST

All authors declare that there was no support from any organization for the submitted paper, no financial relationships with any organizations that might have an interest in the submitted study and no other relationships or activities that might appear to have influenced the submitted study.

Figures

Figure 1
Figure 1
Oocytes retrieved from cycles performed in women with an ORPI <0.5 for each protocol.
Figure 2
Figure 2
Number of days of stimulation in cycles of women with an ORPI <0.5 for each protocol.
Figure 3
Figure 3
Oocytes retrieved from the cycles of women with an ORPI [0.5-0.9] for each protocol.
Figure 4
Figure 4
Number of days of stimulation in the cycles of women with an ORPI [0.5-0.9] for each protocol.
Figure 5
Figure 5
Oocytes retrieved from the cycles of women with an ORPI ≥ 0.9 for each protocol.
Figure 6
Figure 6
Number of days of stimulation in the cycles of women with an ORPI ≥ 0.9 for each protocol.
See this image and copyright information in PMC

References

    1. Al-Inany HG, Abou-Setta AM, Aboulghar M. Gonadotrophin-releasing hormone antagonists for assisted conception: a Cochrane review. Reprod Biomed Online. 2007;14:640–649. doi: 10.1016/S1472-6483(10)61059-0. - DOI - PubMed
    1. Alyasin A, Mehdinejadiani S, Ghasemi M. GnRH agonist trigger versus hCG trigger in GnRH antagonist in IVF/ICSI cycles: A review article. Int J Reprod Biomed. 2016;14:557–566. doi: 10.29252/ijrm.14.9.557. - DOI - PMC - PubMed
    1. Amanvermez R, Tosun M. An Update on Ovarian Aging and Ovarian Reserve Tests. Fertil Steril. 2016;9:411–415. doi: 10.22074/ijfs.2015.4591. - DOI - PMC - PubMed
    1. Biljan MM, Mahutte NG, Dean N, Hemmings R, Bissonnette F, Tan SL. Effects of pretreatment with an oral contraceptive on the time required to achieve pituitary suppression with gonadotropin-releasing hormone analogues and on subsequent implantation and pregnancy rates. Fertil Steril. 1998;70:1063–1069. doi: 10.1016/S0015-0282(98)00333-1. - DOI - PubMed
    1. Blumenfeld Z. The Ovarian Hyperstimulation Syndrome. Vitam Horm. 2018;107:423–451. doi: 10.1016/bs.vh.2018.01.018. - DOI - PubMed

Substances